Biomimetic Biomembrane Encapsulation and Targeted Delivery of a Nitric Oxide Release Platform for Therapy of Parkinson's Disease.
Zhixin HuangBinbin HuBohan XiangHuaqiang FangBingzhen ZhangYing WangYi ZhuoDan DengXiaolei WangPublished in: ACS biomaterials science & engineering (2023)
The existence of the blood-brain barrier (BBB) and the complex inflammatory environment in the brain are two major obstacles in the treatment of Parkinson's disease (PD). As a target group, we modified the red blood cell membrane (RBCM) on the surface of upconversion nanoparticles (UCNPs) in this study to effectively target the brain. Mesoporous silicon, coated with UCNPs (UCM), was loaded with S-nitrosoglutathione (GSNO) as the nitric oxide (NO) donor. Then, UCNPs were excited to emit green light (540 nm) by 980 nm near-infrared (NIR). In addition, it produced a light-responsive anti-inflammatory effect by promoting the release of NO from GSNO and lowering the brain's level of proinflammatory factors. A series of experiments demonstrated that this strategy could effectively mitigate the inflammatory response damage of neurons in the brain.
Keyphrases
- lps induced
- inflammatory response
- nitric oxide
- resting state
- photodynamic therapy
- white matter
- toll like receptor
- functional connectivity
- cerebral ischemia
- oxidative stress
- anti inflammatory
- cancer therapy
- drug delivery
- spinal cord
- blood brain barrier
- fluorescence imaging
- hydrogen peroxide
- stem cells
- brain injury
- multiple sclerosis
- mesenchymal stem cells
- cell therapy
- bone marrow
- replacement therapy
- drug release